<DOC>
	<DOCNO>NCT00993655</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , carboplatin , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) give different way may kill tumor cell . It yet know combination chemotherapy regimen effective treat patient ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer . PURPOSE : This randomized phase II trial compare side effect three combination chemotherapy regimens see well work treat patient stage IIB , stage IIC , stage III , stage IV ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Comparing Combination Chemotherapy Regimens Treating Patients With Stage IIB , Stage IIC , Stage III , Stage IV Ovarian Epithelial Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine intraperitoneal platinum-based chemotherapy lead 9 month progression free survival rate compare intravenous chemotherapy patient stage IIB-III stage IV ( basis pleural effusion positive cytology ) ovarian epithelial , serous type peritoneal , fallopian tube cancer receive optimal debulking surgery follow neoadjuvant intravenous chemotherapy . - To identify two IP regimen continue expand phase II portion trial . - To compare efficacy select IP plus IV chemotherapy regimen versus IV carboplatin plus paclitaxel patient . Secondary - To compare IP plus IV chemotherapy versus IV carboplatin plus paclitaxel respect progression free survival , overall survival , toxic effect , quality life , economic evaluation . - To determine component nurse intervention associate administer intraperitoneal therapy correlate intervention treatment efficacy , toxic effect , quality life . OUTLINE : This multicenter study . Patients stratify accord cooperative group , residual disease ( observable [ e.g. , macroscopic ] disease evident end delay primary debulking surgery v evidence observable disease end delay primary debulking surgery ) , reason delay primary debulking surgery initial diagnosis ( nonresectable disease v reason ) , time intraperitoneal catheter insertion ( intra-operative catheter insertion v post-operative insertion ) . - Phase II : Patients randomize 1 3 treatment group . - ARM 1 : Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 measure GFR AUC6 estimate GFR intravenous day 1 ; Paclitaxel 60 mg/m2 intravenous day 8 . Cycles give Q 21 day x 3 cycle - ARM 2 : Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1 ; Paclitaxel 60 mg/m2 intraperitoneal day 8 . Cycles give Q 21 day x 3 cycle ( Phase II cisplatin arm close accrual 2014-Feb-03 ) - ARM 3 : Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 measure GFR AUC6 estimate GFR intraperitoneal day 1 ; Paclitaxel 60 mg/m2 intraperitoneal day 8 . Cycles give Q 21 day x 3 cycle . Patients also receive carboplatin IP day 1 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . - Expanded Phase II : Patients randomize 1 2 treatment group . - Arm I : Patients receive paclitaxel carboplatin phase II , arm I . - Arm III : Patients receive paclitaxel cisplatin phase II , arm II paclitaxel carboplatin phase II , arm III . Patients complete quality life questionnaire EORTC QLQ-C30 , ovarian cancer module ( EORTC QLQ-OV28 ) , FACT/GOG-Ntx baseline , day 1 course 2 3 , 3 , 6 12 month completion study treatment , annually disease progression , death , initiation second-line therapy . After completion study treatment , patient follow 6 week , every 3 month 2 year , every 6 month 2 year , annually progression , death , initiation second-line therapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , primary serous type peritoneal , fallopian tube carcinoma Patients ovarian cancer clear cell histology eligible . Histologic confirmation preferably biopsy limited excision prior neo‐adjuvant treatment . If diagnosis prior neoadjuvant chemotherapy base cytology , histologic confirmation require prior randomization . Histologic confirmation obtain time debulking surgery intraoperative frozen section , thus permit intraoperative randomization , final pathologic review resect specimen randomization perform follow debulking surgery . Initial FIGO stage IIBIII disease Stage IV disease allow provided criterion stage IV disease presence pleural effusion confirm associate positive cytology ovarian cancer Completed ≥ 3 4 course platinumbased neoadjuvant chemotherapy prior first debulking surgery Meets follow criterion surgical treatment prior randomization : Initial Diagnosis : No debulking surgery attempt complete . The patient 's first cytoreductive ( debulking ) surgery must neoadjuvant chemotherapy ( Delayed Primary Debulking ) . The delayed primary debulking surgery must complete 4 week commence administer last cycle neoadjuvant chemotherapy must complete 6 week prior randomization . Surgery include total abdominal hysterectomy , bilateral salpingooophorectomy , omentectomy additional procedure require achieve maximal cytoreduction residual disease 1 cm less assessed surgeon end surgery . Delayed primary debulking surgery must complete 4 week last course neoadjuvant chemotherapy must complete 6 week prior randomization Surgery include total abdominal hysterectomy , bilateral salpingooophorectomy , omentectomy , additional procedure require achieve maximal cytoreduction residual disease ≤ 1 cm assess surgeon end surgery No borderline ovarian tumor ( i.e. , tumor low malignant potential ) alone No mucinous tumor PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Granulocyte count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Serum creatinine ≤ upper limit normal ( ULN ) OR &gt; ULN ≤ 1.25 ULN provide measure creatinine clearance &gt; 60 mL/min Serum bilirubin normal AST/ALT ≤ 2.5 time ULN Fertile patient must use effective contraception Able ( i.e. , sufficiently fluent ) willing complete quality life questionnaires Accessible treatment followup No history malignancy , except adequately treat nonmelanoma skin cancer , curatively treat carcinoma situ cervix , solid tumor curatively treat evidence disease ≥ 5 year No uncontrolled atrial ventricular arrhythmia include second third degree heart block unless manage implanted pacemaker Patients history first degree heart block eligible No document myocardial infarction within past 6 month precede randomization ( pretreatment ECG evidence infarct exclude patient ) No diagnosis bowel obstruction No serious illness medical condition would permit patient manage accord protocol include , limited , follow : Prior allergic reaction drug contain cremophor compound chemically related cisplatin , paclitaxel , carboplatin Symptomatic congestive heart failure within past 6 month condition would lead contraindication highvolume saline diuresis History significant neurologic psychiatric disorder would impair ability obtain consent Active uncontrolled infection Persistent peripheral neuropathy hearing loss ≥ grade 2 result prior therapy Extensive intraperitoneal adhesion intra postoperatively would impede intraperitoneal treatment delivery PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior therapy ovarian cancer , except neoadjuvant platinumbased chemotherapy surgery No concurrent intraperitoneal adhesion barriers No concurrent anticancer treatment , include cytotoxic agent , biological response modifier , immunotherapy , anticancer hormone therapy , investigational drug therapy No concurrent experimental drug anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>malignant pleural effusion</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian clear cell tumor proliferating activity</keyword>
</DOC>